NBME-style questions › CNS Pharmacology
CNS Pharmacology · Pharmacology · NBME-Style

CNS Pharmacology — NBME-style practice question

A physician-validated, board-style question from the Active Transport QBank. Try it, then check the reasoning for every option.

A 65-year-old woman presents with memory problems for the past few weeks. Patient vividly describes how she forgot where she put her car keys this morning and did not remember to wish her grandson a happy birthday last week. Patient denies any cognitive problems, bowel/bladder incontinence, tremors, gait problems, or focal neurologic signs. Patient mentions she wants to take Ginkgo because her friend told her that it can help improve her brain function and prevent memory loss. Past medical history is significant for an acute cardiac event several years ago. Current medications are aspirin, carvedilol, and captopril. Patient denies any history of smoking, alcohol or recreational drug use. Patient is a widow, lives alone, and is able to perform all activities of daily living (ADLs) easily. No significant family history. Patient is afebrile and vital signs are within normal limits. Physical examination is unremarkable. Which of the following would be the most appropriate response to this patient’s request to take Ginkgo?

↑ Tap an answer to reveal the reasoning
Answer: B. This patient describes age-appropriate forgetfulness with intact ADLs, normal exam, and no red flags for dementia - she does not need pharmacologic 'memory enhancers.' The teaching point is the drug interaction created by Ginkgo biloba. She is already on aspirin (and carvedilol/captopril) after a prior cardiac event, so antiplatelet therapy is essential. Ginkgo biloba inhibits platelet-activating factor (PAF) and has antiplatelet effects on its own. When combined with aspirin, NSAIDs, clopidogrel, or warfarin, ginkgo significantly increases bleeding risk - including spontaneous subarachnoid and subdural hemorrhages reported in the literature. The appropriate physician response is to counsel the patient against ginkgo specifically because of this bleeding risk, not because of vague concerns about herbal regulation. This is also a good model of evidence-based counseling about supplements: ginkgo has weak and inconsistent evidence for cognitive benefit in any population, so a 'risk without proven benefit' framing is appropriate. **Why each option:** **A.** Ginkgo is widely used but evidence for memory benefit is weak; recommending it without addressing the bleeding interaction with aspirin would be unsafe. **B.** Correct. Ginkgo has antiplatelet effects (via PAF inhibition) and on top of aspirin substantially raises the risk of bleeding, including intracranial hemorrhage - the safety-critical response. **C.** Herbal preparations including ginkgo carry real risk of adverse events; assuring her there is 'no risk' is factually wrong and would expose her to bleeding harm. **D.** While true that herbal supplements are minimally FDA-regulated, the specific and actionable reason to decline ginkgo in THIS patient is the additive bleeding risk with aspirin, not a generic regulatory argument.

Want 12,000 more like this?

Practice the full physician-validated NBME-style QBank, matched to your own notes — free for 7 days, no credit card.

Start your free Pro trial →
← Browse more free NBME-style questions